WuXi Biologics (Cayman) revenue and financials

2269 · HKEX · HKD

$56.70−2.07%−$1.20

Close · October 7, 2026

In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.

Annual revenue · 2025: ¥21.79B

¥10.29B2021
¥15.27B2022
¥17.03B2023
¥18.68B2024
¥21.79B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +16.68%; 2025 vs 2024
Net income growth: +46.25%; 2025 vs 2024
Net margin: 22.5%; 2024: 18.0%

Financial data

Amounts in millions of CNY; per-share values in CNY; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q4 2025	Q2 2025	Q4 2024	Q2 2024	Q4 2023	Q2 2023	Q4 2022	Q2 2022	Q4 2021
Total revenue	11,787	11,837	9,953	10,101	8,574	8,542	8,492	8,062	7,206	5,883
Cost of revenue	6,339	6,071	5,700	5,800	5,224	5,275	4,931	4,751	3,793	3,351
Gross profit	5,448	5,766	4,253	4,301	3,350	3,267	3,561	3,311	3,413	2,532
Selling, general and administrative	1,183	1,262	1,051	1,151	996	1,004	785	845	587	593
Research and development	430	510	344	422	344	444	341	412	271	386
Operating income	3,728	3,922	2,724	2,766	1,820	1,630	2,302	1,866	2,484	1,530
EBIT	3,728	3,922	2,724	2,766	1,820	1,630	2,302	1,866	2,484	1,530
EBITDA	4,546	4,476	3,449	3,356	2,493	2,075	2,853	2,167	2,902	1,697
Interest expense	44.6	59.5	83.5	89.5	68.1	79.7	78.8	41.7	22.7	18.3
Pre-tax income	3,419	3,929	3,328	2,826	2,008	1,645	2,529	2,428	2,930	1,935
Income tax	503	952	571	661	228	412	191	499	309	309
Net income	2,440	2,569	2,339	1,857	1,499	1,133	2,267	1,885	2,535	1,546
Net income to common shareholders	2,440	2,569	2,339	1,857	1,499	1,133	2,267	1,885	2,535	1,546
Basic EPS	0.60	0.64	0.58	0.46	0.37	0.27	0.55	0.45	0.61	0.37
Diluted EPS	0.58	0.61	0.55	0.44	0.35	0.25	0.52	0.43	0.58	0.35
Average shares (basic)	4,097	4,029	4,026	4,061	4,103	4,169	4,158	4,170	4,176	4,198
Average shares (diluted)	4,181	4,166	4,186	4,198	4,256	4,348	4,350	4,365	4,386	4,436